Edwards Lifesciences Corporation (EW)
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally.
Scored against other Healthcare stocks, not a fixed scale.
The quick read
Edwards Lifesciences is right in the middle: the good and the not-so-good roughly cancel out.
- What's working
- It carries less debt and has more breathing room than most other healthcare companies.
- Worth watching
- Its price is high compared with other healthcare companies, given its sales and profits.
Analyst price target
~12-month · 26 analystsPublished targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
About Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally…
- Sector
- Healthcare
- Industry
- Medical Devices
- Employees
- 16,000
- Headquarters
- Irvine, CA
Similar stocks
What’s behind the score
Valuation
P/E 51.5 — lower than 7% of Healthcare peers
P/B 4.7 — lower than 46% of Healthcare peers
P/S 7.7 — lower than 20% of Healthcare peers
EV/EBITDA 23.3 — lower than 17% of Healthcare peers
EV/Revenue 7.1 — lower than 27% of Healthcare peers
PEG 1.9 — lower than 41% of Healthcare peers
FCF yield 2.5% — higher than 24% of Healthcare peers
Profitability & quality
Gross margin 77.8% — higher than 90% of Healthcare peers
Operating margin 29.8% — higher than 70% of Healthcare peers
Net margin 15.4% — higher than 63% of Healthcare peers
ROE 9.2% — higher than 41% of Healthcare peers
ROA 8.4% — higher than 62% of Healthcare peers
Free cash flow is 126% of reported net income
Financial health
Debt/equity 0.1 — lower than 96% of Healthcare peers
Current ratio 4.52 — higher than 97% of Healthcare peers
Quick ratio 3.45 — higher than 97% of Healthcare peers
Cash/debt 6.04 — higher than 100% of Healthcare peers
Debt/EBITDA 0.35 — lower than 93% of Healthcare peers
Growth
Revenue growth 13.6% YoY — higher than 83% of Healthcare peers
Earnings growth -25.4% YoY — higher than 19% of Healthcare peers
Ownership & investor activity
Payout ratio 0.0% — somewhat unusual vs Healthcare peers
Net insider buying, +32.3% of insider shares
Institutions net sold, -12.5% of shares held
Insiders hold 0.2% of shares outstanding
1.9% of float sold short
Momentum
Mixed vs its moving averages
56% of the way from its 52-week low to high